EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Betaine alleviates MASLD through hepatic N6-methyladenosine (m6A)-dependent translational regulation

Jingsu Yu, Tengda Huang, Haisen Song, Qiuchen Cheng, Yinzheng Li, Xiangling Li, Zhaoxuan Ding, Qingqing Huo, Min Zhao, Wenqian Nong, Zupeng Luo, Siqi Liu und 7 weitere

Frontiers in Pharmacology · 18.11.2026 · 17

DOI: 10.3389/fphar.2026.1962619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Jingsu Yu und 18 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

N6-methyladenosine (m6A) methylation is emerging as a key regulator of mRNA translation, but its role in metabolic dysfunction-associated steatotic liver disease (MASLD) remains poorly understood. Whether betaine, a methyl donor, alleviates hepatic steatosis through m6A-mediated translational regulation has not been explored.

Methods

A high-fat diet (HFD)-induced MASLD mouse model, with or without betaine intervention, was analyzed using integrated multi-omics approaches, followed by in vitro validation.

Results

Betaine ameliorated HFD-induced hepatic steatosis and liver injury. Integrative analysis revealed betaine-induced alterations in m6A methylation, and genes bearing differential m6A peaks were enriched in lipid metabolism and autophagy pathways. Notably, m6A modifications, particularly in coding regions, were associated with enhanced translation of target genes. Protein-protein interaction (PPI) analysis highlighted ANKHD1 as a hub gene. In vitro , betaine reduced lipid accumulation and enhanced ANKHD1 translation, whereas ANKHD1 knockdown attenuated the lipid-lowering effect of betaine, suggesting a potential role for ANKHD1 in the hepatoprotective action of betaine.

Conclusion

This study provides a comprehensive characterization of m6A-mediated translational regulation in betaine-induced amelioration of hepatic steatosis. Our findings suggest that the m6A- ANKHD1 axis may contribute to betaine’s beneficial effects on MASLD, and identify ANKHD1 as a potential therapeutic target. These insights may inform nutritional strategies for improving hepatic lipid metabolism in livestock production.

Zitieren

APA

Yu, J., Huang, T., Song, H., Cheng, Q., Li, Y., Li, X., Ding, Z., Huo, Q., Zhao, M., Nong, W., Luo, Z., Liu, S., Yu, L., Liang, Y., Liang, X., Zheng, K., Li, Y., Zhou, L., & Liang, Y. (2026). Betaine alleviates MASLD through hepatic N6-methyladenosine (m6A)-dependent translational regulation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1962619

Vancouver

Yu J, Huang T, Song H, Cheng Q, Li Y, Li X, et al. Betaine alleviates MASLD through hepatic N6-methyladenosine (m6A)-dependent translational regulation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1962619

BibTeX
@article{Yu2026,
  author = {Yu, Jingsu and Huang, Tengda and Song, Haisen and Cheng, Qiuchen and Li, Yinzheng and Li, Xiangling and Ding, Zhaoxuan and Huo, Qingqing and Zhao, Min and Nong, Wenqian and Luo, Zupeng and Liu, Siqi and Yu, Lin and Liang, Yuehui and Liang, Xue and Zheng, Ke and Li, Yixing and Zhou, Lei and Liang, Yunxiao},
  title = {Betaine alleviates MASLD through hepatic N6-methyladenosine (m6A)-dependent translational regulation},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1962619}
}
Kostenlos starten →